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Summary
More than a quarter of a century of research has established chronic
immune activation and dysfunctional T cells as central features of chronic
HIV infection and subsequent immunodeficiency. Consequently, the
search for a new immunomodulatory therapy that could reduce immune
activation and improve T-cell function has been increased. However, the
lack of small animal models for in vivo HIV study has hampered progress.
In the current study, we have investigated a model of cord blood haemat-
opoietic progenitor cells (CB-HPCs) -transplanted humanized NOD/LtsZ-
scidIL-2Rcnull mice in which progression of HIV infection is associated
with widespread chronic immune activation and inflammation. Indeed,
HIV infection in humanized NSG mice caused up-regulation of several
T-cell immune activation markers such as CD38, HLA-DR, CD69 and
co-receptor CCR5. T-cell exhaustion markers PD-1 and CTLA-4 were
found to be significantly up-regulated on T cells. Moreover, increased
plasmatic levels of lipopolysaccharide, sCD14 and interleukin-10 were also
observed in infected mice. Treatment with minocycline resulted in a sig-
nificant decrease of expression of cellular and plasma immune activation
markers, inhibition of HIV replication and improved T-cell counts in
HIV-infected humanized NSG mice. The study demonstrates that minocy-
cline could be an effective, low-cost adjunctive treatment to regulate
chronic immune activation and replication of HIV.
Keywords: HIV; humanized NOD/LtsZ-scidIL-2Rcnull mice; immune acti-
vation; minocycline.
Introduction
Chronic immune activation is a hallmark of HIV patho-
physiology.1 Current understanding suggests that persis-
tent antigenic stimulation, microbial translocation,
disruption of T-cell homeostasis and various co-infections
initiate and perpetuate chronic immune activation and
dysfunction of T cells.2,3 Highly active antiretroviral ther-
apy (HAART) has been successful in suppressing virus
replication and improving overall immune function in
HIV-infected individuals. However, even after several
years on HAART, markers of immune cell activation,
proliferation, apoptosis and soluble markers of inflamma-
tion do not reach baseline levels in HIV-infected individ-
uals.4–6 Elevated immune activation is associated with
progression towards AIDS in non-treated patients and to
non-opportunistic infections, cardiovascular disease,
lipodystrophy, renal disease, alteration in bone metabo-
lism and an increased risk of non-AIDS-defining malig-
nancies in individuals on HAART.1 Persistent immune
activation, which disrupts the functional organization of
the immune system and reduces its regenerative capacity,
has emerged as a potential determinant of HIV-associated
morbidity and mortality.7
Development of new immunomodulatory therapies to
curb HIV-associated immune activation and T-cell dys-
function has been hampered by lack of in vivo experimental
models. The inherent differences between SIV and HIV
pathogenesis,8,9 along with the prohibitive cost for using
non-human primates, have slowed the search for novel
therapies to combat chronic immune activation induced
by HIV. The new generation of humanized NOD/LtsZ-
scidIL-2Rcnull (NSG) or NSG-bone marrow-liver-thymus
(BLT) mouse models sustain a long-term HIV replication
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and mimic the immune activation phase of HIV patho-
genesis.10–12 Hence, they provide a new opportunity for
in vivo trials to predict the efficacy of new therapies.
Recently, an antibiotic from the tetracycline fam-
ily – minocycline – has been proposed as anti-HIV adju-
vant therapy.13,14 It fits into a new unique class of drug
in possessing both immunomodulatory and anti-viral
properties against SIV and HIV. In the experimental SIV
model of HIV central nervous system disease, minocy-
cline has a strong influence in reducing the severity of
encephalitis and neurodegeneration through the reduction
of monocyte activation and the suppression of p38 and
c-jun-n-terminal kinase (jnk) activation pathways, which
are essential for the generation of inflammatory media-
tors.15,16 An in vitro study has shown that minocycline
affects activation-induced markers (CD69, HLA-DR,
CD25, CCR5 and Ki-67) expression and secretion of cyto-
kines [interleukin-2 (IL-2), interferon-c (IFN-c) and
tumour necrosis factor-a (TNF-a)] from T cells.14 Previ-
ous studies have also shown that minocycline has strong
anti-viral properties. Minocycline treatment of SIV-
infected macaques significantly lowers their viral RNA in
cerebrospinal fluid and plasma.17,18 Zink et al. observed
92 and 99% reduction in HIV replication (HIV-1Bal and
HIV-1III) at a 40 lg/ml dose of minocycline in lympho-
cytes and macrophages.17 In another in vitro study using
a 20 lg/ml dose, minocycline-treated T cells showed a
twofold decrease in HIV-1 NL4-3 infectivity.14 Computa-
tional docking and molecular dynamics simulation studies
have also proposed high binding affinity of minocycline
for HIV-1 integrase.19
In a clinical trial for the treatment of HIV-associated
cognitive impairment, minocycline was found to be safe
and tolerable in HIV-infected individuals.20 In another
recent pilot study, minocycline nevertheless failed to
modulate cerebrospinal fluid HIV infection and immune
activation.21 However, this study had several inherent
design limitations, including its size, short duration of
study and more importantly, absence of an untreated
control group for comparison. Hence, potential role and
efficacy of minocycline in the management of HIV-
induced chronic immune activation still needs to be
investigated.
In the present study, we have used humanized NSG
mice transplanted with cord blood-haematopoietic pro-
genitor cells (CB-HPCs),11 to evaluate the therapeutic
potential of minocycline for the treatment of chronic
immune activation induced by HIV-1 infection. HIV
infection in humanized mice caused a chronic activation
of the immune system, and treatment of minocycline at a
dose of 100 mg/kg/day for 60 days led to significantly
lower viral load and improved T-cell count. Expression of
cellular activation (CD38, HLA-DR, CD69 and CCR5)
and exhaustion markers (PD-1 and CTLA-4) was signifi-
cantly lower in the treated group of mice. Level of
sCD14, lipopolysaccharide (LPS) and IL-10 was also
lower in this group of humanized mice.
In summary, we demonstrate that the CB-HPC-trans-
planted humanized NSG mouse model can recapitulate
the HIV-induced chronic immune activation observed in
infected humans and minocycline can be proposed as
adjuvant therapy with HAART to treat the chronic
immune activation and inflammation.
Materials and methods
Mouse conditioning
NSG mice were purchased from Jackson Laboratory
(Bar Harbor, ME). Mice were kept in microisolator cages
and were fed with autoclaved food and water. Experi-
ments on animals were performed according to institu-
tional animal care and research committee guidelines,
ethical application number-670. Busulfan (Sigma Aldrich,
Munich, Germany) was dissolved in DMSO, diluted
with RPMI-1640 and injected intraperitoneally in 3- to
4-week-old mice. Mice received 50 mg/kg of busulfan as
two doses of 25 mg/kg with a 12-hr interval.
Transplantation of CB-HPCs and HIV inoculation in
NSG mice
Human cord blood (CB) was obtained from the Cord
Blood Bank Central Hospital University (Liege, Belgium)
after obtaining informed consent. CB mononuclear cells
were obtained after Ficoll–Hypaque density gradient cen-
trifugation and CD34+ haematopoietic stem cells were
isolated from CB mononuclear cells using a magnetic-
activated cell sorting CD34+ progenitor cell isolation kit
(Stem Cell Technologies, Grenoble, France) according to
the manufacturer’s instructions. After three-time enrich-
ment, 96% of CD34+ cells were positively selected. We
transplanted 2 9 105 freshly isolated CD34+ cells into
mice by intravenous tail injection within 16–24 hr of a
second busulfan injection. Infection and maintenance
of NSG mice were performed in GIGA-R-Biosafety
Level 3 facilities under standard caging conditions. After
130–150 days of CB-HPC transplantation, nine groups of
mice (n = 70) (Table 1) were inoculated with HIV-
1JRCSF (5000 TCID50) by intraperitoneal route. Group 5,
6, 7 and 8 mice were treated with minocycline at a dose
of 100 mg/kg/day by intraperitoneal injection. Six mice of
group 9 were used to measure the basal level of cytokines
and LPS in the plasma samples.
Flow cytometry of activation markers
Peripheral blood was collected from the tail vein of mice
at 10-day intervals. Red blood lysis was performed before
labelling with antibodies and cells were phenotyped by
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using BD FACSCanto II Flow Cytometer (BD Biosciences,
Erembodegem, Belgium). Antibodies used for flow
cytometric analysis were allophycocyanin-conjugated anti-
human CD45, FITC-conjugated anti-human CD4, phyco-
erythrin-conjugated anti-human CD38, CD69, PD-1,
CTLA-4, HLA-DR and peridinin-chlorophyll protein-
conjugated anti-human CD8 from BD Biosciences. We
also used phycoerythrin-conjugated anti-human CCR5
from R&D Systems (Abingdon, UK). Human leucocyte
reconstitution of CD4 and CD8 cells was enumerated
using a BD Trucount tube (BD Biosciences, Erembode-
gem, Belgium). The absolute numbers of cells were calcu-
lated using the BD trucount equation.
Viral load determination
The viral load was determined using Cobas ampliPrep/co-
bas TaqMan HIV-1 Test, version 2.0 (v2.0) (Roche, Vil-
voorde, Belgium). This is an automated in vitro nucleic
acid amplification test for the quantification of HIV-1
RNA in plasma using the Cobas ampliPrep instrument.
We processed 20 mouse samples for each time-point.
Fifty microlitres of murine plasma samples was diluted
with 950 ll of assay diluent and processed with control
seropositive and seronegative human plasma samples.
Measurement of sCD14 and LPS in plasma
Sixty days after HIV inoculation, 100 ll of plasma sam-
ples was used to determine LPS levels with the EndoLISA
LPS measurement kit (Hyglos GmbH, Bernried,
Germany). Reagents were prepared in LPS-free glass tubes
and LPS-free tips and disposables were used. Levels of
sCD14 were measured by quantikine human sCD14
immunoassay (R&D Systems).
Cytokine levels
Levels of cytokines IL-2, IL-4, IL-6, IL-10, IFN-c and
TNF-a were quantified with 50 ll of plasma using a BD
CBA human enhanced sensitivity kit and the master
buffer kit or CBA human Th1/Th2 Cytokine Kit II (BD
Biosciences, Erembodegem, Belgium) according to the
manufacturer’s instructions. Data were acquired with
FACS Canto and analysed using FCAP ARRAY software.
Statistical analysis
Statistical analysis was performed using GRAPHPAD PRISM
software. Data were expressed as the mean value  stan-
dard deviation (SD). Significant differences between data
groups were determined by two-sample Student’s t-test
analysis. A P-value < 005 was considered to be signifi-
cant. Two-tailed Spearman correlation coefficient (r) was
calculated, with resulting P-values at 95% confidence.
Results
Effect of minocycline on viral load and T-cell count
HIV replicated efficiently in the humanized mouse model
as early as 10 days after HIV inoculation and viral load
was around 5 log copies/ml in both groups (untreated
and minocycline-treated) of humanized mice (n = 20,
each group) (Table 1) (Fig. 1a). At 10 days after HIV
inoculation, the untreated group of mice had a viral load
of 495  034 log copies/ml that steadily increased to
620  060 log copies/ml at day 60. Twenty days after
HIV inoculation, viral load remained constant in the
minocycline-treated group. It was around 517  055 at
day 30 after HIV inoculation and remained similar
520  055 at day 60. Compared with the untreated
infected group of humanized mice, viral load in the
minocycline-treated group of mice was significantly lower
at day 30 (P = 0020), 40 (P = 00054), 50 (P = 00001)
and 60 (P < 00001).
Number of CD4+ T cells decreased after HIV inocula-
tion in both groups of humanized mice (Fig. 1b). Before
HIV inoculation, the concentration of CD4+ T cells in
untreated mice was 5284  3308 cells/ll and it rapidly
decreased by roughly 50% to 2546  6671 cells/ll after
20 days of infection. At day 0 in HIV-infected,
Table 1. Groups of humanized mice and experimental analysis performed
Group number Number of mice Minocycline-treated HIV inoculation Analysis performed
1 10 No Yes CD38, T cells/ll, viral load
2 10 No Yes PD-1, T cells/ll, viral load
3 6 No Yes HL-DR, CD69, sCD14
4 6 No Yes CCR5, CTLA-4, cytokines, lipopolysaccharide (LPS)
5 10 Yes Yes CD38, T cells/ll, viral load
6 10 Yes Yes PD-1, T cells/ll, viral load
7 6 Yes Yes HL-DR, CD69, sCD14
8 6 Yes Yes CCR5, CTLA-4, cytokines, LPS
9 6 No No Cytokines, LPS
ª 2014 John Wiley & Sons Ltd, Immunology, 142, 562–572564
M. Singh et al.
minocycline-treated mice the CD4+ T-cell number was
5131  3904 cells/ll and it decreased to 3093  6137
cells/ll at 20 days after HIV inoculation. CD4+ T-cell
decline was much slower during the remaining period of
the study. Fifty days after HIV inoculation, the
minocycline-treated group had more CD4+ T cells,
1855  5013 cells/ll, compared with the untreated
group, 1292  4463 cells/ll (P = 00006), of humanized
mice. Similarly, at day 60, the minocycline-treated group
had more CD4+ T-cells, 1616  5508 cells/ll, compared
with the untreated group of mice, 1013  3889 cells/ll
(P = 00003).
HIV infection also caused a slow but steady decrease in
the number of CD8+ T cells in the untreated group of
mice. Compared with CD4+ T cells, the decline of the
CD8 cell count was less drastic. The most significant
decline of CD8+ T cells occurred during the first 10 days
of infection (Fig. 1c). During this period, CD8+ T-cell
number declined from 2256  7977 to 1742  4369
cells/ll in the untreated humanized mice, whereas the
drop was less pronounced in the minocycline-treated
group (from 2450  8270 to 1828  4381 cells/ll). In
the remaining 50 days of the study, there was a small
decline of CD8+ T-cell number in the minocycline-treated
group (1828  4381 to 1485  4932 cells/ll). How-
ever, during the same period, there was a sharp decline of
CD8+ T cells in the untreated group and the CD8 count
was only 975  4428 cells/ll 60 days after HIV inocula-
tion. Interestingly, we observed a strong inverse correla-
tion (r = 0602; P < 00001) between viral load and
CD4 count in HIV-infected untreated humanized mice
(Fig. 1d). In the minocycline-treated group of humanized
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Figure 1. Viral load and T-cell count in HIV-infected non-treated and minocycline-treated mice. (a) HIV viral load during 60 days of HIV infec-
tion in non-treated (open boxes) and minocycline-treated (solid black boxes) humanized mice. (b, c) CD4 and CD8 T cells/ll during 60 days of
HIV infection in non-treated (open boxes) and minocycline-treated (solid black boxes) humanized mice. (d) Strong inverse correlations of
human CD4 cell count with the plasma viral load during 60 days of infection in HIV-infected non-treated humanized mice (open circle: non-
treated). (e) Weaker inverse correlations between human CD4 count and plasma viral load in infected minocycline-treated humanized mice (solid
circle: non-treated). Error bars indicate standard deviation. Results are presented as mean  SD. P values were determined by unpaired Student’s
t-tests. *P < 005, **P < 001 and ***P < 0001. Linear regression along with trend lines from analysis are shown, and the two-tailed Spearman
correlation coefficient (r) was calculated, with resulting P values at 95% confidence.
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Effect of minocycline on CD38 mean florescence
intensity on T cells
CD38 expression on CD8+ cells is a surrogate marker for
HIV disease progression.22,23 The expression level of CD38
on CD8+ T cells strongly correlates directly with the viral
load and indirectly with CD4 cell count.24 Peripheral
blood leucocytes from HIV-infected untreated (n = 10)
and minocycline-treated humanized mice (n = 10) were
assessed for CD38 mean fluorescence intensity (MFI) on
CD4+ and CD8+ T cells. We performed CD38 expression
analysis seven times, at 10-day intervals (Fig. 2a, c). The
MFI of CD38 expression increased soon after HIV inocu-
lation. Minocycline-treated mice had lower levels of CD38
expression on CD4+ T cells compared with the untreated
humanized mice. The more pronounced difference of
CD38 MFI on CD4+ T cells was observed at day 50
(5477  1518 versus 7697  1130, P = 00016) and day
60 (5719  1486 versus 8251  1916, P = 00040) after
HIV inoculation between the minocycline-treated and
untreated groups (Fig. 2a). MFI of CD38 on CD8+ T cells
remained significantly different between two groups of
mice starting from 20 days after HIV inoculation. At the
last three time-points of analysis, MFI was 8984  1067,
9638  1419 and 10 096  1737 in minocycline-treated
group of humanized mice and much higher in the
untreated group at 10 756  850 (P = 00007),
12 192  8099 (P = 00001) and 12 806  1090
(P = 00006), respectively (Fig. 2b).
Several former studies have shown that CD38 expression
on CD8+ T cells is well correlated with plasma viral load.24
Hence we verified the correlation between viral load and
the frequency of CD38 expression on CD8+ T cells in the
HIV-infected humanized mice. In the untreated group of
infected humanized mice the MFI of CD38 on CD8+
T cells was moderately correlated with HIV viral load
(r = 0365; P = 00041) (Fig. 2c). In the minocycline-trea-
ted group, the MFI of CD38 on CD8+ T cells was weakly
correlated with the viral load (r = 0261; P = 00439)
(Fig. 2d). We also observed a strong inverse correlation
between CD38 MFI on CD8+ and CD4+ T-cell counts in
untreated (r = 0637; P < 00001) (Fig. 2e) and minocy-
cline-treated (r = 0705; P < 0001) (Fig. 2f) humanized
mice groups. Levels of CD69, CCR5 and HLA-DR also dif-
fered between infected non-treated and minocycline-trea-
ted groups (see Supporting information, Fig. S1).
Minocycline limits the expression of immune
exhaustion markers PD-1 and CTLA-4
In HIV-infected individuals, PD-1 and CTLA-4 expression
on T cells is driven by viral replication and associated with
T-cell exhaustion and immune cell dysfunction.25,26
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Figure 2. Expression of cellular immune activation marker CD38 on T cells. (a, b) Change in mean florescence intensity of CD38+ on CD4 and
CD8 T cells in the peripheral blood on HIV-infected non-treated (open bars) and HIV-infected minocycline-treated (solid black bars) humanized
NSG mice during 60 days of infection. Results are presented as mean  SD. P-values were determined by unpaired Student’s t-tests. *P < 005,
**P < 001 and ***P < 0001. (c–f) Mean florescence intensity of CD38 on CD8 T cells correlates with viral load and inversely to CD4 count in
HIV-infected non-treated mice (open circle: non-treated and solid circle: minocycline-treated). Linear regression along with trend lines from
analysis are shown, and the two-tailed Spearman correlation coefficient (r) was calculated, with resulting P values at 95% confidence.
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Peripheral blood leucocytes from HIV-infected non-treated
(n = 10) and minocycline-treated (n = 10) humanized
mice were analysed seven times at 10-day intervals to deter-
mine the frequency of PD-1-expressing cells. This
frequency increased after HIV inoculation in both groups
of mice. Minocycline-treated humanized mice had a signif-
icantly lower level of PD-1-expressing CD4 cells at day 20
after HIV inoculation. At day 50, it was 474  115% in
the minocycline-treated group and 611  80% in non-
treated mice (P = 00071). On day 60, it was 524  86%
in the minocycline-treated mice and 6686  82% in non-
treated mice (Fig. 3a). The frequency of CD8 T cells
expressing PD-1 also differed between infected non-treated
and minocycline-treated mice as soon as 30 days after HIV
inoculation. At day 50, the frequency of CD8+ PD-1+ T
cells was 512  68% in the minocycline-treated group
and 638  58% (P = 00003) in non-treated mice. Sixty
days after HIV inoculation, this frequency was
715  58% in the non-treated and 608  80%
(P = 00030) in the minocycline-treated group (Fig. 3b, g).
PD-1 expression on CD4+ T cells has been shown to cor-
relate positively with viral load and inversely with CD4+
T-cell count.25 Accordingly, we observed a strong correla-
tion between the frequency of CD4+ PD-1+ T cells and
viral load in non-treated mice (r = 0588; P < 00001)
(Fig. 3c) whereas this correlation was weak in the minocy-
cline-treated mice (r = 0138; P = 02911) (Fig. 3d). How-
ever, there was a strong inverse correlation with CD4 cells/
ll in both minocycline-treated (r = 0750; P < 00001)
and non-treated (r = 0744; P < 00001) groups (Fig. 3e,
f).
It has also been shown that up-regulation of CTLA-4
on CD4+ T cells correlates with HIV disease progression
and defines a reversible immune dysfunction in infected
individuals.27 We measured CTLA-4 frequency at days 0,
30 and 60 after HIV inoculation in non-treated (n = 6)
and minocycline-treated (n = 6) humanized mice and
observed a significant increase in CTLA-4 expression on
CD4+ T cells. Compared with non-treated mice, the fre-
quency of CD4 T cells expressing CTLA-4 was signifi-
cantly lower in the minocycline-treated group. Thirty
days after HIV inoculation, untreated mice had a
CD4+ CTLA-4+ frequency of 419  68%, which was
significantly higher (P = 00258) than what was observed
in minocycline-treated mice (318  80%). This differ-
ence was even more significant (P = 00035) at day 60.
The frequency of CD8+ CTLA-4+ T cells was much lower
compared with CD4+ T cells in both groups of mice and
there was no difference between non-treated and minocy-
cline-treated mice (Fig. 3h, i).
Effect of minocycline on LPS, sCD14 and IL-10
Increased microbial translocation from the gastrointestinal
tract has been implicated in driving the chronic immune
activation observed in HIV-infected individuals.28
We measured LPS levels in plasma samples of non-infected,
infected untreated and infected minocycline-treated
humanized mice. LPS level was below the detection limit in
non-infected humanized mice (n = 6). Infected untreated
mice (n = 6) had significantly higher levels of LPS
(1004  330 EU/ml), compared with minocycline-trea-
ted mice (050  020 EU/ml) (P < 0001) (n = 6)
(Fig. 4a). An increased level of sCD14 is a marker of mono-
cyte response to LPS in HIV-infected individuals.29 Non-
infected mice (n = 6) had 1245  710 ng/ml of sCD14.
The levels of sCD14 significantly increased
(1563  1370 ng/ml) in infected untreated mice (n = 6).
Minocycline-treated mice (n = 6) had significantly lower
levels of sCD14 (1351  548 ng/ml) (P = 00025) com-
pared with untreated infected mice (Fig. 4b).
HIV infection resulted in disruption of homoeostasis of
cytokine profiles. Levels of cytokines increased signifi-
cantly in infected mice (n = 6 each group) compared
with non-infected mice (n = 6) (see Supporting informa-
tion, Fig. S2). However, only the IL-10 level differed
significantly (3257  3590 versus 3687  2062 pg/ml,
P = 00033) between infected untreated and infected
minocycline-treated mice (Fig. 4c).
Discussion
The results presented here demonstrate that NSG mice
humanized by transplantation of CB-HPCs and infected
with HIV emulate the chronic immune activation state
observed during HIV infection in humans. They further-
more show that a chronic treatment with minocycline has
a significant inhibitory effect on HIV replication and on
expression levels of cellular/plasma immune activation
markers in humanized mice.
Because of the inherent complexity of HIV-associated
immune activation and the existence of controversies
regarding its mechanism, it is difficult to draw parallels
for all aspects of HIV-associated immune activation
observed in humans with those observed in this murine
model in a single study. However, features such as the
increased expression of activation (CD38, HLA-DR,
CD69 and CCR5) and exhaustion markers (PD-1 and
CTLA-4) are precisely described in humans. It is also the
case for the increased levels of circulating LPS and
sCD14. Moreover, the strong correlation between CD38+
MFI and PD-1 expression with the viral load and CD4
count are also similarly present in human infection and
in our model. Early establishment of T-cell activation
highlights the relevance of this phenomenon for the path-
ogenesis of HIV disease in our murine model. Studies
performed on HIV-infected individuals have also sug-
gested that the immune activation set point is established
during the early acute phase of infection and is responsi-
ble for determining the rate of disease progression.30
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Figure 3. Frequencies of T cells expressing immune exhaustion markers PD-1 and CTLA-4. (a, b) Change in frequencies of CD4 PD-1+ and CD8
PD-1+ T cells in the peripheral blood in HIV-infected non-treated (open bars) and HIV-infected minocycline-treated (solid black bars) human-
ized NSG mice during 60 days of infection. Frequency of CD4 PD-1+ T cells strongly positively correlated with viral load (c) and CD4 cells/ll
(e) in HIV-infected non-treated mice (open circle: non-treated). Weaker correlation existed between the frequency of CD4 PD-1+ T cells and
viral load in minocycline-treated groups of mice (d, solid circle: minocycline) but a stronger correlation was found with CD4 cell/ll (f). (g) Dot
plot for PD-1 frequency on CD4 and CD8 cells. Acquisition gate was set on human CD45 cells and further gatings were performed on CD4 and
CD8 cells. (h, i) Frequency of CTLA-4 on CD4 and CD8 T cells of peripheral blood, at days 0, 30 and 60 after HIV infection. Results are pre-
sented as mean  SD. P values were determined by unpaired Student’s t-tests. *P < 005, **P < 001 and ***P < 0001. Linear regression along
with trend lines from analysis are shown, and the two-tailed Spearman correlation coefficient (r) was calculated, with resulting P values at 95%
confidence.
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Unlike what has been described in the humanized BLT-
NSG model,10,31 we have also observed a strong and
inverse correlation between viral load and CD4 count in
the course of infection. This allowed us to investigate and
to evaluate the potential of minocycline as a way to pre-
vent the establishment of HIV-associated immune activa-
tion during the acute phase of infection.
Our study in humanized NSG mice suggests that mino-
cycline inhibits both HIV replication and the expression
of chronic immune activation markers. HIV infection is a
self-perpetuating cycle in which HIV replication drives
chronic immune activation, which further promotes repli-
cation of the virus. Based on previous observations, we
can speculate that minocycline can interrupt this vicious
cycle at various steps as its immunomodulatory effects
are well recognized.32–35 Szeto et al., showed that minocy-
cline has indeed a strong influence on the expression of
activation markers and cytokines after in vitro stimulation
of non-infected T cells.14 Recently, it was also shown that
minocycline administered in a vaginal microbicidal prepa-
ration, down-regulates the activation of CD4+ T cells and
the recruitment of immune cells into vaginal tissues of
mice challenged with HIV-1.36 Another report suggests
that minocycline acts by suppressing activation of the
nuclear factor of activated T cells 1 (NFAT-1) in CD4+ T
cells.37 Hence, our observations of lower levels of HIV-
associated activation markers (CD38, HLA-DR, CCR5)
are consistent with previous reports and possibly reflect
the effect of minocycline on NFAT-1 function.
One of the direct consequences of immune activation
is the facilitation of virus replication. In SIV-infected
macaques and in HIV-infected individuals, immune acti-
vation was correlated with the induction of viral replica-
tion in vivo.38 We can therefore make a link between the
blunted immune activation and the lower levels of viral
load in minocycline-treated mice. However, it is difficult
to formally establish the direction of the causality
between immune activation and virus replication because
a direct role of minocycline in inhibiting HIV replication
cannot be ruled out. Previous studies have indeed pre-
dicted high binding affinity of minocycline to HIV-1
integrase.19 Moreover, blocking of nuclear factor-jB
induction by minocycline could also interfere with HIV-1
transcription and infection in T cells.39 Significantly lower
viral loads have also been observed in plasma samples of
SIV-infected rhesus macaques treated with minocycline.18
It is known that substantial decline of CD4+ T cells in
untreated HIV infection is the result of apoptosis of
T cells.18 Increased caspase-3 activity is observed in indi-
viduals with progressive HIV infection and caspases have
been associated with HIV-mediated apoptosis.40,41 Mino-
cycline has been shown to interfere with both caspase-
dependent and independent cell death processes.42–44
Hence higher T-cell numbers in HIV-infected minocy-
cline-treated mice might be the result of direct anti-
apoptotic effects.
Microbial translocation of commensal microbial prod-
ucts from the gut into the systemic circulation plays a
key role in driving chronic persistent immune activation
in HIV-infected individuals.45 A strong correlation
between plasma LPS level and the frequency of circulating
activated CD38+ HLA-DR+ CD8 T cells is reported in
HIV-infected individuals.46,47 We have also observed
increased levels of LPS in the plasma of HIV-infected
humanized mice, as previously reported in other stud-
ies.47,48 Increased secretion of TNF-a has been proposed
as a cause for increased intestinal permeability by disrupt-










































Figure 4. Levels of lipopolysaccharide (LPS), sCD14 and interleukin-10 (IL-10) in plasma of non-infected, infected non-treated and infected
minocycline-treated mice. (a) Significant difference in plasma LPS levels in between infected non-treated and infected minocycline-treated mice.
LPS levels were below detection limits in non-infected age-matched mice (b, c). Higher plasma sC14 and IL-10 levels in HIV-infected mice com-
pared with the other two groups (open bars: HIV-infected non-treated, solid black bars: HIV-infected minocycline-treated, solid grey bars: non-
infected non-treated mice). Results are presented as mean  SD. P values were determined by unpaired Student’s t-tests. *P < 005, **P < 001
and ***P < 0001.
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epithelial cells in HIV-infected humanized RAG/ c/
mice.48 Interestingly, we also found increased TNF-a lev-
els in our model of HIV-infected mice; however, it is
noteworthy that, in our hands, minocycline had no sig-
nificant effect on plasma levels of TNF-a (Fig. S2) despite
the associated strong reduction of microbial translocation.
We postulate that the observed difference in LPS levels
might be a direct antibiotic effect of minocycline leading
to an overall reduction of intestinal bacterial load and
therefore, to reduced microbial translocation. This
assumption is supported by the fact that minocycline has
a 38-fold higher concentration in bile than in serum49
and has been shown to decrease the bacterial load of
colon and caecum.50 Furthermore, minocycline might
also play a role in preserving gut integrity as it attenuates
nitric oxide synthase and matrix metalloproteinase syn-
thesis and preserves gut integrity in an experimental
model of colitis.51 We also found significant differences
in sCD14 levels between minocycline-treated and non-
treated HIV-infected humanized mice. To our knowledge,
it is the first study to measure levels sCD14 in
HIV-infected humanized mice.
HIV infection leads to a significant increase in cytokine
levels in infected humanized mice. Interestingly, we did
not observe any difference in levels of cytokines between
HIV-infected non-treated and minocycline-treated groups
except for IL-10, which was significantly higher in the
infected non-treated group. This observation does not
correspond with previous findings, which suggested that
minocycline can preclude nuclear factor-jB translocation
and impede the mitogen-activated protein kinase path-
ways and therefore, block the secretion of pro-inflamma-
tory cytokines.52–54 The reason for this discordance is not
clear. It is conceivable that the strong inhibition of IL-10
(a cytokine with anti-inflammatory properties) by mino-
cycline has irrevocably antagonized its direct inhibitory
effects on the other cytokines. Additional experiments are
needed to clarify this point.
Persistent antigenic stimulation during HIV infection
leads to immune exhaustion with subsequent loss and
proliferative capacity of effector T cells. It is also charac-
terized by up-regulation of PD-1 and CTLA-4 expression
on T cells. We observed a significant difference in the
levels of expression of these markers between infected
non-treated and minocycline-treated groups. Minocycline
had been earlier shown to regulate levels of NFAT-1 in T
cells.37 The observed difference in the levels of PD-1
expression on T cells might be correlated to this finding
because NFAT-1 regulates NFATc1 levels, on the one
hand,55 and NFATc1 regulates levels of PD-1 expression
on T cells on the other.56,57 Therefore, minocycline regu-
lation of PD-1 expression on T cells via NFAT-1/NFATc1
cannot be ruled out, although further experiments might
be needed to verify this correlation. Moreover, it is also
known that NFAT-1 directly regulates levels of CTLA-4
expression,57 which is suppressed by minocycline in
T cells. It would be interesting to find out if the blunting
of PD-1 expression by minocycline is also associated with
improved CD8+ T-cell function, especially directed
against HIV antigens. This could pave the way for the use
of minocycline as an adjunctive treatment during thera-
peutic vaccine trials aimed at restoring an efficient anti-
HIV immune function in chronically infected patients.
In summary, our data demonstrate that immune
activation observed in HIV-infected individuals can be
modelled in HIV-infected humanized NSG mice. This
model is therefore, an effective tool to dissect the mecha-
nisms involved. Moreover, the potential of therapeutic
interventions to reduce persistent T-cell activation in the
setting of HIV infection can be screened more rapidly in
this humanized NSG mouse model. The encouraging
results observed in this study confirm that minocycline
has potential as an anti-HIV therapy, specifically in the
context of immune activation and inflammation.
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online version of this article:
Figure S1. Frequency of T cells expressing immune
activation markers CD69, HLA-DR A and co-receptor
CCR5 (a, b) Frequency of early immune activation mar-
ker CD69 on CD4 and CD8 T cells of peripheral blood at
day 0, 7 and 14 after HIV infection. (c, d) CCR5
frequency on CD4 and CD8 T cells at days 0, 30 and 60
after HIV infection in peripheral blood of humanized
mice. (e, f) Frequency of HLA-DR on T cells from
peripheral blood of humanized mice. Open bars:
HIV-infected non-treated; solid bars: HIV-infected
minocycline-treated. Error bars indicate standard devia-
tion. Results are presented as mean  SD. P values were
determined by unpaired Student’s t-tests. *P < 005,
**P < 001 and ***P < 0001.
Figure S2. Levels of cytokines in plasma samples. (a, b,
c, d, e) Levels of interleukin-2 (IL-2), IL-4, IL-6, inter-
feron-c (IFN-c )and tumour necrosis factor-a (TNF-a)
cytokines in humanized mice. Open bars: HIV-infected
non-treated; solid black bars: HIV-infected minocycline-
treated; and solid grey bars: non-infected and minocy-
cline-treated. Error bars indicate standard deviation.
Results are presented as mean  SD. P-values were deter-
mined by unpaired Student’s t-tests. *P < 005,
**P < 001 and ***P < 0001.
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